24 November 2017
News and Views
Links and Services
Cognitive behavior therapy in addition to mebeverine for IBS is cost-effective, finds the most recent issue of the European Journal of Gastroenterology & Hepatology.
Irritable bowel syndrome (IBS) is often treated in primary-care settings, and it has a relatively
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors